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Abstract
Background: Immunization against beta-amyloid (Aβ) is a promising approach for the treatment of Alzheimer’s
disease, but the optimal timing for the vaccination remains to be determined. Preventive immunization approaches
may be more efficacious and associated with fewer side-effects; however, there is only limited information available
from primate models about the effects of preclinical vaccination on brain amyloid composition and the
neuroinflammatory milieu.
Methods: Ten non-human primates (NHP) of advanced age (18–26 years) and eight 2-year-old juvenile NHPs were
immunized at 0, 2, 6, 10 and 14 weeks with aggregated Aβ42 admixed with monophosphoryl lipid A as adjuvant,
and monitored for up to 6 months. Anti-Aβ antibody levels and immune activation markers were assessed in
plasma and cerebrospinal fluid samples before and at several time-points after immunization. Microglial activity was
determined by [11C]PK11195 PET scans acquired before and after immunization, and by post-mortem
immunohistochemical and real-time PCR evaluation. Aβ oligomer composition was assessed by immunoblot
analysis in the frontal cortex of aged immunized and non-immunized control animals.
Results: All juvenile animals developed a strong and sustained serum anti-Aβ IgG antibody response, whereas only
80 % of aged animals developed detectable antibodies. The immune response in aged monkeys was more delayed
and significantly weaker, and was also more variable between animals. Pre- and post-immunization [11C]PK11195
PET scans showed no evidence of vaccine-related microglial activation. Post-mortem brain tissue analysis indicated a
low overall amyloid burden, but revealed a significant shift in oligomer size with an increase in the dimer:pentamer
ratio in aged immunized animals compared with non-immunized controls (P< 0.01). No differences were seen in
microglial density or expression of classical and alternative microglial activation markers between immunized and
control animals.
Conclusions: Our results indicate that preventive Aβ immunization is a safe therapeutic approach lacking adverse
CNS immune system activation or other serious side-effects in both aged and juvenile NHP cohorts. A significant
shift in the composition of soluble oligomers towards smaller species might facilitate removal of toxic Aβ species
from the brain.
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Background
Passive and active immunization against beta-amyloid
(Aβ) has been proven efficacious in removing Aβ aggre-
gates from the brain [1-3]. In rodents, this clearance was
associated with cognitive improvement in many but not
all studies [4-9], whereas only marginal differences were
noted in cognitive outcome measures between vacci-
nated and non-vaccinated humans [10-12]. Moreover,
serious side-effects including meningoencephalitis in a
subset of patients and the development of vasogenic
edema have complicated human immunization studies
[13,14].
One possible explanation for the lack of success in
human studies might be the timing of therapeutic
intervention. Aβ species begin to accumulate in the
brain many years to decades before cognitive symp-
toms develop [15]. At the time of enrollment into
vaccination studies, patients with a clinical diagnosis
of probable Alzheimer’s disease (AD) have already
developed secondary neurodegenerative changes in-
cluding tau accumulation, synaptic pathology, neu-
ronal loss, angiopathy, and neuroinflammation, which
may be irreversible and thus unaffected by reducing
the brain Aβ burden [13,16]. Therefore, if immunization
therapy were to be efficacious, it would probably need
to be administered earlier. Studies in transgenic
mouse models have already shown that Aβ accumula-
tion in the brain and cognitive deficits can be mark-
edly diminished by preventive immunization strategies
initiated before the onset of significant Aβ deposition
[1,2,8]. In addition, vaccination at a time when the
brain amyloid burden is still low may reduce the risk
of toxic side-effects mediated by soluble amyloid spe-
cies that might possibly be released from disaggre-
gated plaques, and may decrease the risk of cerebral
amyloid angiopathy-associated microhemorrhages pro-
moted by amyloid shift from parenchyma to the vas-
culature [17].
Based on these considerations, there are increased
efforts to start immunization during a crucial time
window of preclinical AD when Aβ pathology is still
minimal [13,16,18]. The development of improved
biomarker panels and ima-ging paradigms (Pittsburgh
Compound B (PiB) PET scans [19]) may soon allow
the more accurate identification of individuals at risk
who may benefit most from early intervention. Bio-
markers of interest include CSF Aβ42, phospho-tau
and tau levels [20,21] and more novel markers such
as YKL40, which may help distinguish between con-
trol, mild cognitive impairment (MCI) and mild AD
[18,22,23].
To date, preventive immunization approaches have not
been studied in a non-human primate (NHP) model, there-
fore we sought to evaluate the effects of immunization on
the aging NHP brain before the onset of a significant Aβ
burden by addressing the following questions:
1) Does active Aβ vaccination in an individual with low
amyloid burden alter the level and composition of
Aβ species in the brain or CSF?
2) Is preventive immunization associated with
microglial activation or shifts in the
neuroinflammatory milieu?
3) Does immunosenescence affect the efficacy of
preventive Aβ immunization in an aging population?
Methods
Animals
All animals were housed and maintained according to
strict standards of the Association for Assessment and
Accreditation of Laboratory Animal Care, and experi-
ments were approved by the University of Pittsburgh Insti-
tutional Animal Care and Use Committee.
In total, 10 aged macaques (aged 18 to 26 years; 5 rhesus,
1 cynomolgus and 4 pigtailed macaques; 2 males, 8 females)
and 8 juvenile pigtailed macaques (1 to 2 years; all male)
were included in the immunization protocol. Archival brain
tissue and fluid samples from age-matched aged macaques
(18–21 years; 4 rhesus, 2 cynomolgus; all male) and juvenile
macaques (1–2 years; 11 pigtailed; 5 males, 6 females)
were used as non-immunized control samples in some
experiments as detailed below. Unless otherwise indicated,
experiments were performed on all animals in each
treatment cohort.
Vaccine preparation
Beta-amyloid 1–42 (Aβ42; American Peptide Company,
Sunnyvale, CA, USA) was dissolved in sterile PBS
(1 mg/ml), mixed by vortex for 5 minutes and subse-
quently incubated at 37°C for 24 hours to allow for
aggregation [2]. Synthetic monophosphoryl lipid A
(MPL; InvivoGen, San Diego, CA, USA) was solubilized
in DMSO and diluted in sterile water for a final concen-
tration of 0.5 mg/ml. Single vaccine aliquots were pre-
pared by mixing 100 μl of Aβ stock solution (equal to
100 μg) with 200 μl of MPL adjuvant solution, and these
were then stored at −20°C until use.
To assess the animals’ general immune responsiveness,
a control vaccine consisting of tetanus and diphtheria
toxoid (Massachusetts Public Health Biologic Laboratories,
Boston, MA, USA) was administered in accordance with
the manufacturer’s dosing instructions.
Study timeline
Amyloid vaccines were administered subcutaneously at 0,
2, 6, 10, and 14 weeks. Tetanus–diphtheria vaccines were
given at 0 and 4 weeks in the contralateral appendage.
EDTA plasma and serum samples were collected before
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the first vaccination and every 2 weeks thereafter through-
out the study period. CSF samples were drawn before
vaccination and either every 2 weeks (aged animals) or
4 weeks (juveniles) throughout the study period. All samples
were collected in the morning, between 08.00 and 10.00 AM,
to minimize circadian fluctuations. Blood and CSF samples
were stored in aliquots at −80°C until further analysis.
Animals were monitored for at least 16 weeks. If no
rise in anti-Aβ antibody titer had occurred by that time-
point, the study period was extended for another 8 weeks
for a total of 24 weeks. Any animal that did not develop
a measurable antibody concentration by 24 weeks was
classified as a non-responder.
[11C]PK11195 PET scans were performed at baseline
and after development of an antibody response (around
weeks 12 to 16). In non-responders, the follow-up scan
was performed at the end of the study period (weeks 20 to
24). PET scans could not be performed on two of the aged
animals for logistical reasons. One additional aged animal
received a baseline scan but not a post-immunization scan
because of technical difficulties.
(R)-[N-methyl-11C]PK11195 ([11C]PK11195) positron
emission tomography imaging
[11C]PK11195 was synthesized at the University of
Pittsburgh PET Facility as previously described [24]. [11C]
PK11195 PET scans were acquired with the use of a PET
scanner (either microPET P4 or ECAT HR+; Siemens
Medical Systems, Knoxville, TN, USA) operating in three-
dimensional (volume imaging) mode. For smaller animals
(<10 kg), the microPET P4 scanner was used for imaging.
This scanner has a 220 mm animal port that simultaneously
acquires 63 image planes over an 80 mm axial field of view
(FOV) with a maximum reconstructed image spatial reso-
lution of ~1.8 mm full width at half maximum (FWHM)
[25]. Animals too large to be accommodated by the
microPET P4 system were imaged using the ECAT HR+
scanner, which is a clinical PET tomograph that simultan-
eously acquires 63 image planes over a 152-mm axial FOV
with an intrinsic spatial resolution of ~4.5 mm FWHM.
Before radiotracer injection, transmission scans were
performed for attenuation correction of PET emission
data. Transmission scans were conducted using either a
~130 MBq (3.5 mCi) rotating 57Co point source (microPET
P4) or 68Ga68Ge rod sources. Attenuation correction factors
were calculated from back-projection and segmentation
of the transmission image (microPET P4) or measured
directly (ECAT HR+). Following the transmission scan,
311±52 MBq (8.4±1.4 mCi) (range 255 to 429 MBq; 6.9 to
11.6 mCi) of [11C]PK11195 with high specific activity
(>55.5 GBq/μmol (1.5 Ci/μmol) at time of injection(TOI))
was injected intravenously into each macaque over a period
of 30 seconds. PET data were acquired for 90 minutes in a
dynamic series of 33 frames and corrected for attenuation,
dead time, scatter, and radioactive decay. [11C]PK11195
PET scans of each macaque were co-registered to the
baseline PET scan using the normalized mutual information
algorithm implemented in the PMOD software package
(PMOD Technologies, Zurich, Switzerland). Volumes of
interest (VOI) were defined bilaterally on summed PET
images (0 to 8 minutes post-injection) for cerebral cortex
(combined region covering the frontal, lateral temporal, and
parietal cortices), thalamus, cerebellum, and subcortical
white matter. VOIs were applied to the dynamic emission
data to generate regional time–activity concentration
curves. Regional radioactivity concentrations were summed
over the post-injection interval of 10 to 60 minutes, and
normalized to that in the subcortical white matter (SWM)
to estimate the specific retention of [11C]PK11195 as previ-
ously described [26,27].
[11C]Pittsburgh compound- B (11C]PiB) positron emission
tomography imaging
[11C]PiB was synthesized at the University of Pittsburgh
PET Facility using the captive solvent method as previ-
ously described [28]. [11C]PiB-PET images were acquired
on both microPET P4 and ECAT HR+PET scanners as
described above for the [11C]PK11195 studies. Following
the completion of the transmission scan, 377± 85 MBq
(10.2± 2.3 mCi) (range: 296 to 537 MBq; 8.0 to 14.5 mCi])
of high specific activity (>22.2 GBq/μmol (0.6 Ci/μmol)
at TOI) [11C]PiB was injected intravenously over 30
seconds. PET data were acquired for 90 minutes in a
dynamic series of 33 frames, and corrected for attenuation,
dead time, scatter, and radioactive decay. Regional [11C]
PiB retention measures for frontal cortex, temporoparietal
cortex, thalamus, and pons were determined using the
late scan (40 to 90 minutes) standardized uptake value
ratio (SUVR) method and the cerebellum as reference as
previously described [29].
Anti-Aβ40, anti-Aβ42 and anti-toxoid IgG antibody
measurements
Anti-Aβ antibody levels in plasma and CSF were measured
by ELISA using published protocols with minor modifica-
tions [30-32]. In brief, 96-well ELISA plates (Immulon
2HB; ThermoFisher Scientific, Pittsburgh, PA, USA) were
coated overnight with solubilized Aβ40 or Aβ42 (American
Peptide Company, Sunnyvale, CA, USA) in bicarbonate
coating buffer, pH 9.6 (Bethyl, Montgomery, TX, USA).
After washing twice with washing solution (0.1% Tween-
20 in PBS), the wells were blocked first with blocking buf-
fer (SuperBlock; ThermoFisher Scientific) followed by an
additional blocking step with 5% milk in PBS-Tween. Sam-
ples (100 μl per well) were then incubated for 2 hours at
room temperature. After three washes, horseradish perox-
idase-conjugated anti-monkey IgG detection antibody
(1:30,000; Rockland, Gilbertsville, PA, USA) was added to
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each well for 1 hour. After five washes, 100 μl of tetra-
methylbenzidine substrate (Sigma, St. Louis, MO, USA)
was dispensed into each well. After 15 minutes, the devel-
oping color reaction was stopped with 50 μl of 1 mol/l
HCl solution. Optical density was immediately measured
at 450 nm using a microplate reader (ELx800; BioTek,
Winooski, VT, USA).
Serum anti-tetanus toxoid antibody levels were mea-
sured by ELISA (IBL, Minneapolis, MN, USA). Similar
results were achieved using the anti-human detection
antibody supplied with the kit as with an anti-monkey
IgG detection antibody, thus all subsequent experiments
were performed using the reagents in the kit. Results are
expressed as IU/ml.
Aβ40, Aβ42, total tau, and YKL40 measurements
Aβ40, Aβ42, and YKL40 concentrations were measured
in CSF and plasma using ELISA kits according to the
manufacturers’ protocols (Aβ1-40 and Aβ1-42 (Invitro-
gen, Camarillo, CA, USA) and YKL40 (Quidel Corpor-
ation, San Diego, CA, USA)). CSF samples were also
assessed for total tau concentration by ELISA (Invitrogen).
In addition to absolute concentrations, the tau to Aβ42
ratio was calculated for CSF samples.
Multiplex analysis of neuroimmune marker
Commercial cytokine assay kits (Procarta; Panomics,
Fremont, CA, USA) were used to simultaneously detect
one human-specific cytokine (macrophage colony-
stimulating factor; M-CSF) and 30 NHP-specific proteins
in CSF samples. These assays were based on detection
technology (xMAP; Luminex Corp., Austin, TX, USA)
that uses beads to quantitatively measure multiple
cytokines in a small amount of sample. Cytokines were
quantified at baseline before vaccination and weeks 4 and
16 after immunization. CSF samples were diluted 1:2 in
buffer (Non-human Primate Bodily Fluid Buffer;
Panomics) and processed according to the manufacturer’s
recommendations. The plate was read at the University of
Pittsburgh Cancer Institute Luminex Facility (Bio-Plex
reader Luminex 100, Luminex Corp.). Analyte concentra-
tions were calculated based on the respective standard
curve for each analyte.
Determination of Aβ levels in the brain by immunoblot
and ELISA
Tissue fractionation and extraction was performed as
previously described [33]. Briefly, the frontal cortex
(0.1 g) was homogenized in 0.4 ml of buffer containing
NaCl–Pi pH 7.4, 0.32 mol/l sucrose, 50 mmol/l Hepes,
25 mmol/l MgCl2, 0.5 mmol/l dithiothreitol, and phos-
phatase and protease inhibitor cocktails (Calbiochem, San
Diego, CA, USA). The samples were separated by centrifu-
gation for 10 minutes at 1000 g and 4°C. Supernatants were
transferred into appropriate ultracentrifuge tubes, and the
pellets were rehomogenized in 0.3 mL of buffer, then sepa-
rated again by centrifugation for 10 minutes at 1000 g and
4°C. The second supernatant was collected and combined
with the first supernatant and separated by centrifugation
for 1 hour at 100,000 g and 4°C. This final supernatant was
collected to serve as the cytosolic fraction, and the
remaining pellet was resuspended in 0.2 mL of buffer and
rehomogenized to give the membrane fraction. The
bicinchoninic acid protein assay was used to determine the
protein concentration of the samples.
For immunoblot analysis, samples (20 μg) were loaded
onto a 4 to 12% Bis-Tris gel (Invitrogen, Carlsbad, CA,
USA) and run with MES–SDS running buffer (NuPAGE;
Invitrogen) at 200 V for 45 minutes on ice. Gels were trans-
ferred to a 0.2 μm nitrocellulose membrane, in transfer buf-
fer (1 l Tris-glycine buffer containing 20% methanol) at
400 mA for 1.5 hours. Membranes were boiled in phos-
phate-buffered saline for 5 minutes, blocked with 3% BSA
in Tris-buffered saline and 0.05% Tween 20 (TBS-T) for 1
hour, and incubated overnight at 4°C with anti-Aβ antibody
(6E10, Signet Laboratories, Dedham, MA, USA). Mem-
branes were washed in TBS-T for 1 hour, and incubated in
secondary antibody for 1 hour at room temperature. Mem-
branes were washed for 30 minutes in TBS-T and then for
five minutes in TBS alone. Detection was carried out with a
commercial reagent (Western Lightning Chemilumines-
cence Reagent Plus; PerkinElmer, Waltham, MA, USA) and
visualized by enhanced chemiluminescence. Membranes
were analyzed with a Versadoc XL imaging apparatus
(BioRad, Hercules, CA, USA). Analysis of actin levels (C4,
Millipore, Temecular, CA, USA) was used as a loading
control.
Aβ42 concentrations were also measured by ELISA in
accordance with the manufacturer’s protocol (Invitrogen,
Camarillo, CA, USA).
Histopathologic and immunohistochemical evaluation
Animals were killed and perfused with saline, the brains
were then removed immediately and processed for neuro-
pathologic analysis as described previously [34]. Briefly,
brains were bisected sagittally, then the left half was fixed in
10% formalin and tissue blocks were embedded in paraffin
wax, while the right half was micro-dissected and snap-
frozen at −80°C. Sections of brain were stained with
hematoxylin and eosin, or immunostained for the macro-
phage–microglia-associated protein Iba-1 (1:500, Wako
Chemicals USA, Richmond, VA, USA) and the T-cell mar-
ker CD3 (polyclonal, 1:500, Dako, Carpenteria, CA, USA).
The presence of amyloid pathology was evaluated by
Bielschowsky silver stain and immunohistochemical stains
for Aβ (clone 6F/3D, 1:100; Dako (formic acid pre-
treatment)) and total tau (polyclonal antibody, 1:200; Dako).
To assess if vaccination-induced anti-Aβ antibodies bind to
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Aβ plaques, colabeling for Aβ and anti-monkey IgG (1:500,
Rockland, Gilbertsville, PA) was performed.
Prussian blue iron stain was used to screen for microhe-
morrhages. Slides were dewaxed, rehydrated, and immersed
in 10% potassium ferrocyanide for 5 minutes, followed by
immersion in equal parts of 20% hydrochloric acid and
10% potassium ferrocyanide for 30 minutes. Slides were
counterstained with Nuclear fast red.
Quantitative image analysis
Amyloid plaque burden, vascular amyloid, and neurofib-
rillary tangle density were classified using a semi-
quantitative scale (none, minimal, mild, moderate, severe).
Diffuse and neuritic plaque density was scored as none,
minimal, mild, moderate, or severe. Following CERAD
(Consortium to Establish a Registry for Alzheimer's
Disease) guidelines, plaque density was assessed in the
most severely affected area of each evaluated brain
region [35].
Microglial cell density was assessed by single-label Iba-1
immunohistochemistry without counterstaining. Images
(×200 magnification) were taken of random fields in the
mid-frontal cortex (n= 10 fields), hippocampus (5),
entorhinal cortex (5), corpus callosum (3), subcortical
mid-frontal white matter (3), and periventricular white
matter (3). The area fraction immunopositive for Iba-1
was measured using Image J software (http://rsb.info.nih.
gov/ij/) for each image, and the mean value calculated for
each area. The three white-matter regions were combined
into one area.
Quantitative real-time polymerase chain reaction
RNA was isolated from frozen frontal cortex samples using
a commercial kit (RNeasy Mini Kit; Qiagen, Valencia, CA,
USA) in accordance with the manufacturer’s instructions.
RNA concentrations were measured by spectrophotometry
(Nanodrop 1000; ThermoScientific, Wilmington, DE, USA).
After conversion of RNA into cDNA (RETROscript proto-
col; Ambion, Austin, TX, USA), quantitative real-time PCR
was performed (QuantiTect SYBR Green PCR kit; Qiagen)
and NHP-specific primers for the microglial markers CD68
and Iba-1, the astrocyte marker glial fibrillary acidic protein
(GFAP), the classical macrophage activation (M1) markers
CXCL9, CXCL10, prostaglandin-endoperoxide synthase
(PTGS)2 (cyclooxygenase 2), indoleamine 2,3 dioxygenase
(IDO) and CCR7, and the alternative macrophage activation
markers mannose receptor 1 (MRC1:CD206) and CCL17
(Table 1). Primers were designed using Primer3 software
(http://primer3.sourceforge.net/). Samples were run on a
real-time PCR system (StepOnePlus; Applied Biosystems,
Foster City, CA, USA) using standard cycling conditions.
Results are presented as relative gene expression normalized
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as
internal control (2-dCT where dCt=Ct gene of interest − Ct
internal control).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (LaJolla, CA, USA). Comparisons between
groups were performed using the Student’s t-test or, when
data were not normally distributed, the non-parametric
Mann–Whitney U-test. For data with more than one
time-point, repeated measures two-way ANOVA was
performed. P< 0.05 was considered significant.
Results
Antibody response to vaccinations
All eight juvenile animals completed the five-cycle
vaccination protocol and at least 16 weeks of observa-
tion. Of the ten aged macaques, one was diagnosed with
a colon carcinoma during the study period and was
euthanized at week 6, after receiving three of five vaccine
cycles.
Table 1 Primer sequences for microglia and astrocyte cell markers and M1 or M2 activation markers
Gene NCBI reference sequence Forward primer Reverse primer
Iba-1 NM_001047118.1 ccagggatttacagggagga atcgccgtttccattaaggt
CD68 XM_001110126 cagcacagtggacattctcg tgatgagaggcagcaagatg
GFAP XM_001102095.2 aagctccaggatgaaaccaa aacctcctcctcgtggatct
CXCL9 NM_001032936.1 taatgaggaagggtcgctgt tttggctgacctgtttttcc
CXCL10 NM_001032892.1 ttgctgccttgtctttctga tgatggccttagattctgga
IDO NM_001077483.1 ccgtcaagtgtttcagcaaa caggacgtcaaagcactgaa
CCR7 NM_001032884 gtggtggctctccttgtcat gtaggcccacgaaacaaatg
PTGS2 XM_001107538.2 cccttgggtgtgaaaggtaa gccctcgcttatgatctgtc
MRC1 NM_001193925 aaggaaaccatggacaatgc ccatccatccaagcaaactt
CCL17 NM_001032852.1 cttctctgcagcacatccat aacagatggccttgttctgg
GAPDH NM_001195426 tggaaggactcatgaccaca ttcagctcagggatgacctt
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All juvenile animals developed a strong antibody
response against both Aβ42 and Aβ40 after the first or
second vaccine dose, whereas only 80% of the ten aged
animals developed detectable anti-Aβ42 antibodies
(Figure 1A). In five of the eight aged responders, peak
antibody concentrations approached levels similar to
those in the juvenile cohort. The other three aged
responders developed only low antibody levels. In all
aged responders, antibody development was delayed
compared with the juveniles, with minimal antibody
response after the second vaccine dose and increasing
titers after the third dose. Only 60 % of the aged animals
developed anti-Aβ40 antibodies (Figure 1B). Repeated
measures two-way ANOVA analysis showed a strong
effect of age on the immune response for both anti-Aβ42
(F= 81.11; P< 0.0001) and anti-Aβ40 antibody levels
(F= 70.04; P< 0.0001) with significant differences
between age groups from week 4 until the end of the
observation period. These results indicate significant
age-dependent differences in the immune response to
Aβ vaccination.
Age differences were also seen in the response to
tetanus vaccination. Although all aged animals developed
detectable antibody levels, the response was not as
strong as in the juveniles, and required two vaccine-
dosing cycles in all but one aged animal, whereas all
juveniles produced high antibody titers already after the
first dose (Figure 1C). Repeated measures two-way
ANOVA analysis showed a strong effect of age on the
anti-tetanus antibody levels (F= 10.65; P< 0.0001) with
significant differences between age groups from week 2
until week 6.
Anti-Aβ antibody levels in the CSF were determined at
week 16, when serum antibody concentrations were at
peak levels (Figure 2). All juvenile animals contained
detectable anti-Aβ40 and Aβ42 antibodies in the CSF,
although the levels were much lower than in the serum.
By contrast, anti-Aβ42 antibodies were seen in only 44%
of the aged animals, and anti-Aβ40 antibodies in 22%. A
CSF samples was unavailable for one aged animal at
week 16.
IgG immunoglobulins were purified from sera of
animals with a positive anti-Aβ immune response using
protein A spin columns (ThermoFisher, Pittsburgh, PA,
USA) and were found to stain amyloid plaques of a
human brain from a patient with AD, confirming the
specificity of the vaccination-induced antibodies (data
not shown).
Aβ40, Aβ42 and tau levels in cerebrospinal fluid and
plasma
To determine the normal range of Aβ40, Aβ42 and tau in
the CSF of macaques, we first analyzed pre-immunization
samples from all aged and juvenile macaques and also
additional CSF samples from aged and juvenile control
animals. No differences were seen between young and old
animals for Aβ40 and Aβ42 levels (Table 2). The results of
the tau assay revealed a non-significant trend towards
higher levels in the cohort of aged macaques (P=0.06).
Anti-Aβ42 antibodies
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Figure 1 Antibody response curves for plasma anti-Aβ42, anti-Aβ40
and anti-tetanus toxoid in individual juvenile (n = 8) and aged
(n = 10) non-human primates. Significant age-dependent differences
in the immune response against (A) anti-Aβ42, (B) anti-Aβ40 and (C)
tetanus toxoid were evident. Arrows indicate the time-points of (A) Aβ
and (C) tetanus vaccine administrations.
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After immunization, average Aβ40, Aβ42 and tau CSF
levels were not significantly different from baseline levels
for either aged or juvenile animals (Figure 3), but there
was marked variability in individual animals between
pre- and post-immunization levels. A small overall
decrease in CSF Aβ42 and increase in tau concentrations
in the aged cohort resulted in a significant difference in
the post-immunization tau/Aβ42 ratio compared with
juveniles (P< 0.05).
Next, we wanted to determine if changes in CSF Aβ42
concentrations (difference between levels at week 16
post-immunization and baseline; ΔAβ42) were linked to
the immune response. This analysis showed a positive
correlation between ΔAβ42 and week 16 CSF anti-Aβ42
antibody levels, which was significant for the entire
cohort of immunized animals (P< 0.05) and the
subgroup of aged animals (P< 0.05) but not for the
subgroup of juvenile animals. A stronger CSF humoral
immune response was associated with increasing Aβ42
levels in the CSF, whereas declining Aβ42 levels were
seen more frequently in animals with low or undetect-
able CSF anti-Aβ42 antibodies. No correlation was seen
between ΔAβ42 and peak plasma anti-Aβ42 antibody
levels for either aged or juvenile animals.
Pre-immunization plasma concentrations of Aβ40 were
similar in juvenile and aged animals (Table 2). No signifi-
cant changes were seen after immunization in either age
group. Plasma Aβ42 levels were below the detection limit
of our assay before and after immunization in both
juvenile and older macaques.
Aβ content in the brain
Histopathologic evaluation
Post-mortem histopathologic analysis was performed
on all ten immunized aged animals and on six aged non-
immunized control animals. Five immunized and three
non-immunized animals exhibited mild focal Aβ deposits
in their brains, mostly in the form of diffuse plaques, but
rare neuritic plaques were also seen (Table 3). Only one
of the animals had a focus of moderately dense diffuse
plaques. None of the brains exhibited widespread Aβ
deposits. In six animals, the Aβ pathology was restricted
to the cortex, another animal had amyloid deposits in
both cortex and caudate, and one other had Aβ plaques
present exclusively in the head of the caudate nucleus.
Co-labeling for Aβ and IgG did not identify any
antibodies bound to Aβ plaques. In two brains, very focal
vascular amyloid deposits were noted, which in one case
involved very focally leptomeningeal and nearby cortical
vessels, and in the second case, affected a very rare
parenchymal small vessel. Only one of the non-immunized
animals exhibited tau pathology in the form of rare
neurofibrillary tangles in the subiculum, CA1 sector of
the hippocampus and frontal cortex. No apparent
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Figure 2 Antibody levels in cerebrospinal fluid (CSF). (A)
Anti-Aβ42 and (B) anti-Aβ40 antibody levels were significantly lower at
week 16 post-immunization in aged (n = 9) than in juvenile non-human
primates (n = 8). Bars represent median and interquartile range. (C)
Scatterplot displaying the difference (ΔAβ42) between CSF Aβ42 levels at
week 16 and baseline . A significant positive correlation was seen for the
aged (P < 0.05) but not the juvenile cohort.
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differences in the degree of amyloid pathology were
noted between the three macaque strains.
On neuropathologic examination, no additional brain
lesions were seen, other than the presence of axonal
spheroids and hemosiderin deposits in the globus
pallidus of all animals, and variable degrees of vascular
mineralization in the globus pallidus of four animals. No
evidence of meningoencephalitis was seen in any of the
immunized animals.
Immunohistochemical stains for CD3 highlighted
rare perivascular and leptomeningeal T-cells in both
immunized and non-immunized animals. In addition,
focally increased numbers of intraparenchymal
lymphocytes were noted in the white but not gray
matter of some brains. There was no association
between treatment group and the incidence and
density of these parenchymal T-cells. Prussian blue
iron stain did not reveal any microhemorrhages in
the cortex of the aged immunized animals or the
non-vaccinated control animals. Post-mortem patho-
logic examination confirmed the presence of a moder-
ately differentiated mucinous adenocarcinoma in the
right colon of the one animal that had to be killed
before the end of the study period. In addition,
significant age-related non-CNS findings were seen in
several other animals (Table 3).
[11C]PiB positron emission tomography imaging
[11C]PiB scanning was performed in two non-immunized
and six immunized aged macaques at baseline. No signifi-
cant [11C]PiB-PET signal was detected in any of the
analyzed brain regions, indicating a relatively low level of
fibrillar Aβ in these brains [36].
Table 2 Baseline Aβ40, Aβ42 and total tau levels in
cerebrospinal fluid and plasma of juvenile and aged
NHPs (median and interquartile range)
Juvenile animals
(n = 19)
Aged animals
(n = 16)
P-value
Cerebrospinal fluid
Aβ40, pg/ml 1494 (923 to 2077) 1514 (971 to 2145) NS
Aβ42, pg/ml 78.4 (65.3 to 118.4) 107.4 (59.8 to 162.1) NS
Tau, pg/ml 131.4 (89.4 to 168.2) 249.0 (94.2 to 345.2) 0.06
Tau/Aβ42 1.48 (0.84 to 1.94) 1.84 (1.20 to 3.40) NS
Plasma
Aβ40, pg/ml 16.0 (15.1 to 21.0) 15.1 (11.4 to 18.8) NS
Aβ42, pg/ml ND ND
ND, not detected; NS, not significant.
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Figure 3 Concentrations in cerebrospinal fluid of amyloid and tau proteins (A–C) Concentrations of (A) Aβ40, (B) Aβ42 and (C) total tau
before (week 0) and after (week 16) immunization. Bars represent median and interquartile range. No significant differences were seen between
aged (n = 9) and juvenile animals (n = 8) or between baseline and post-immunization levels for either cohort. (D) However, a composite score,
the tau:Aβ42 ratio showed a significant difference between juvenile and aged animals after, but not before, vaccination.
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ELISA and western blot analyses of amyloid load and
oligomer species
Aβ load in the frontal cortex was also determined by
ELISA and showed good correlation with the histopatho-
logic results (Table 3). Only the two animals (one immu-
nized, one non-immunized) with the highest number of
plaques in the frontal cortex as determined by immuno-
histochemistry had Aβ42 levels above the detection limit
of the ELISA. Even though rare diffuse plaques were
seen focally in the frontal cortex of five other animals,
their Aβ42 load remained below the detection limit of
the ELISA.
The amyloid burden was very low and variable within
each group, and there were no differences in overall
amyloid load between immunized and non-immunized
animals. However, further characterization of Aβ species
Table 3 Post-mortem ELISA Aβ42 levels and histopathologic evaluation of amyloid and tau pathology of immunized
and non-immunized aged non-human primates
Animal ID
(age, years)
(species, sex)
Immune
response
Aβ42 content
frontal Cx,
pg/ml
Diffuse
plaques
Neuritic
plaques
Vascular
amyloid
Neuro fibrillary
tangles
Other
pathologic
findings
Immunized animals
CW06-423 (22) (R, M) H BD 0 0 0 0 Colon carcinoma
CW07-220 (22) (R, F) H BD 0/+ (frontal
and insular
cortex)
0/+ (insular
cortex)
+ 0 Mild liver steatosis
CW07-221 (21) (R, F) H BD 0 0 0 0 Multilocular biliary
liver cysts; mild
lung emphysema
CW07-222 (21) (R, F) H BD 0/+ (frontal
cortex);
+ (caudate head)
0/+ (caudate
head)
0 0 Non-necrotizing
granulomatous lung
disease
CW08-237 (20) (P, F) H BD 0 0 0 0 0
CW06-422 (20) (R, M) L BD 0 0 0 0 ND
CW08-236 (20) (P, F) L BD 0 0 0 0 Renal cortical
cysts
CW08-238 (18) (P, F) L 22.17 ++ (patchy
frontal cortex);
0/+ (CA1, entorhinal,
temporal,
insular cortex)
++ (frontal
cortex);
0 0 Papillary renal cell
carcinoma; focal
atypical
adenomatous
hyperplasia of the
lung
CW07-223 (26) (C, F) N BD 0/+ (frontal cortex) 0 0 0 ND
CW08-239 (20) (P, F) N BD + (caudate head) + (caudate
head)
0 0 0
Non-immunized animals
CW06-420 (18) (C, M) N/A BD 0/+ (frontal cortex) 0 0 ++ (subiculum);
+ (CA1, frontal
cortex)
ND
CW06-421 (18) (C, M) N/A 24.61 + (frontal and
temporal cortex)
0 0/+ 0 Renal oncocytoma;
renal cortical
cysts; needle tract
injury of the
spinal cord
CW08-232 (18) (R, M) N/A BD 0 0 0 0 ND
CW08-233 (19) (R, M) N/A BD 0 0 0 0 Organizing
eosinophilic
pneumonia
CW08-234 (21) (R, M) N/A BD 0/+ (frontal cortex) 0 0 0 ND
CW08-235 (19) (R, M) N/A BD 0 0 0 0 ND
0, absent; 0/+, minimal; +, mild; ++, moderate (reflecting most severely affected area in each brain region); BD, below detection limit; C, cynomolgus macaque; Cx,
cortex; F, female; H, high responder; L, low responder; M, male; N, non-responder; N/A, not applicable; ND, not done; P, pigtailed macaque; R, rhesus macaque.
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in the frontal cortex by western blotting identified a
significant shift in oligomer size in the membrane frac-
tion with an increase in the dimer:pentamer ratio in
immunized compared with non-immunized animals
(P< 0.01; Figure 4). No correlation was found between
strength of immune response as determined by peak
anti-Aβ42 antibody levels and dimer:pentamer ratio.
No clear oligomeric bands were seen on blots of the
cytosolic fraction (data not shown).
Assessment of microglial activation
[11C]PK11195 positron emission tomography imaging
To investigate the microglial response to Aβ immunization
in vivo, all juvenile and eight of the ten aged immunized
animals underwent PET imaging using [11C]PK11195, a
selective radioligand of the peripheral benzodiazepine
receptor, also called the 18 kDa translocator protein
(TSPO) [37]. Compared with pre-immunization studies,
no significant changes were seen in any brain region
between pre- and post-immunization scans, although
there was a slight trend towards increased [11C]PK11195
retention over time in the aged but not the juvenile
animals (Figure 5). Subgroup analysis of the aged animals
did not identify any clear trends distinguishing immune
responders from non-responders. As determination of
regional [11C]PK11195 retention required a normalization
step to white matter in this analysis, we were unable to
assess whether there was a global increase in microglial
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Figure 4 Aβ composition in primate brains. (A) Western blot analysis of Aβ oligomers in the membrane fraction of brain extracts from
immunized (n = 10) and non-immunized aged non-human-primates (n = 6) using 6E10 antibody. The left lanes show human brain tissue samples
without Alzheimer’s disease (AD), with mild cognitive impairment, and with AD for comparison. (B) Densitometric analysis showed a significant
difference in the dimer to pentamer ratio in immunized compared with non-immunized aged animals. Bars represent mean ± SD.
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activity in aged compared with juvenile animals. No asso-
ciation was seen between age and cortical [11C]PK11195
retention (relative to white matter), in contrast to
recent reports of significant age-associated increases in
[11C]PK11195 binding found in cognitively normal elderly
humans [38].
Microglial quantification by immunohistochemistry and
real-time PCR
To further evaluate the effects of anti-Aβ immunization
on microglial activity, we quantified the number of
microglial cells by Iba-1 immunohistochemistry in
several brain regions, including the mid-frontal cortex,
entorhinal cortex, hippocampus, corpus callosum, and
white matter. Because the juvenile immunized animals
were not euthanized at the end of the study period, we
were not able to further analyze this cohort of our
animals. The brains from immunized aged animals were
compared with a cohort of non-immunized age-matched
controls. The density of microglial cells was significantly
higher in white matter compared with all three gray
matter regions analyzed (P< 0.05, respectively;
Figure 6A), very similar to the human brain [39]. No
differences were seen between immunized and non-
immunized animals, or between immune responders and
non-responders for any brain region. Animals with
detectable Aβ by immunohistochemistry or ELISA had
cortical microglial densities similar to those of animals
without detectable plaques. These immunohistochemical
findings are supported by the results of quantitative real-
time PCR studies, which showed no differences in the
levels of Iba-1, CD68 or the astrocytic marker GFAP
(Figure 6B).
Taken together, the PET, immunohistochemistry and
PCR data indicate that vaccination against Aβ was not
associated with significant microglial activation in our
cohort of animals. To further define microglial activation
states and evaluate possible shifts in microglial
phenotype, we performed quantitative real-time PCR
studies for several markers of classical (M1) and alterna-
tive (M2) macrophage activation. As there are significant
differences between rodents and humans in M1/M2 gene
signatures [40], we first verified that our set of human
M1/M2 markers is appropriately differentially regulated
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Figure 5 Positron emission tomography imaging analysis. (A) [11C]PK11195 cortex to subcortical white-matter ratio indicated no differences
in microglial activation between juvenile (n = 8) and aged (n = 7) animals before or after immunization. (B) Comparison between pre- and post-
immunization scans showed a trend towards increased [11C]PK11195 retention over time in aged animals. (C) Representative transaxial parametric
image of [11C]PiB standardized uptake value ratio (SUVR) of an aged animal showed no evidence of significant amyloid deposition. The PET image
is superimposed over a corresponding MRI image to aid anatomic orientation. (D, E), Representative transaxial parametric images of [11C]PK11195
cortex to subcortical white-matter ratio (SWMR) revealed no significant microglial activation in (D) aged or (E) juvenile animals.
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in NHP macrophages (unpublished data) before
applying these markers to the brain samples of the
current study. These experiments showed that markers
of both M1 and M2 polarization are expressed in the
brain (Figure 6B). No difference was seen between
immunized and non-immunized aged animals, indicat-
ing that vaccination did not induce a shift in microglial
activation state. No obvious differences were noted
in microglial density or activation markers between
different macaque strains, but group sizes were too
small for definitive conclusions.
Immune activation markers in the CSF
We have previously shown that YKL40 (chitinase 3-like
protein 1; CHI3L1), a member of the glycosyl hydrolase
family 18 lacking hydrolytic activity, is elevated in the
CSF in a variety of acute and chronic neurologic dis-
eases, and is most abundantly associated with astrocytes
in regions of inflammatory cells [22]. To test if Aβ vac-
cination is also associated with significant glial activation,
we measured YKL40 levels in the CSF before and at mul-
tiple time-points after vaccination. At all time-points,
YKL40 concentrations were significantly higher in aged
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Figure 6 Immunohistochemical and real-time (RT) PCR analyses. (A) Immunohistochemical assessment of microglial density in mid-frontal
cortex (MFCx), hippocampus (HI), entorhinal cortex (ECx) and white matter (WM), expressed as the Iba-1-positive area fraction. No differences were
seen in any brain area between immunized (n= 10) and non-immunized aged non-human primates (NHPs) (n= 6). Bars represent mean± SD. (B)
Quantitative RT-PCR analysis of expression of microglial (CD68 and Iba-1) and astrocytic (GFAP) markers as well as indicators of classical (CXCL10,
CXCL9, indoleamine 2,3 dioxygenase (IDO), CCR7, prostaglandin-endoperoxide synthase 2 (PTGS2)) and alternative (CCL17, mannose receptor 1
(MRC1) microglia activation. No significant differences were seen between immunized and non-immunized NHPs for any marker. Mean± SD.
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Figure 7 Analysis of YKL40 release There were significantly higher concentrations of YKL40 in (A) cerebrospinal fluid (CSF) and (B) plasma in
aged (n = 10) than in juvenile (n= 8) animals at baseline in both fluid compartments. No significant changes were seen in the CSF after
immunization (Aged, n= 9; juvenile, n= 8). Mean± SD.
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than in juvenile animals, but there was no significant
change in YKL40 levels after immunization in either age
group (Figure 7A). There was greater variability in post-
immunization CSF YKL40 levels in aged animals, but no
association between YKL40 levels and immune response
was detected. Similar to the CSF results, plasma YKL40
levels were significantly higher in aged than in juvenile
animals (Figure 7B). Two aged animals had substantially
higher plasma YKL40 levels than the remaining cohort.
Both of these animals were eventually diagnosed with
malignancies: one with colon carcinoma, the other post-
mortem with renal cell carcinoma.
CSF samples of aged and juvenile macaques were also
used for multiplex analysis testing of various inflamma-
tory cytokines and growth factors. Results for basic
fibroblast growth factor (bFGF), granulocyte–macrophage
colony-stimulating factor (GM-CSF), interferon-gamma
(IFN-γ), interleukin (IL)-1b, IL-2, IL-4, IL-8, IL-10, IL-12
(p70), IL-15, IL-17a, CCL7 (monocyte chemotactic protein
3 (MCP-3), CXCL9 (monokine induced by gamma inter-
feron; MIG), CCL3 (macrophage inflammatory protein 1a;
MIP-1a), nerve growth factor (NGF), platelet-derived
growth factor (PDGF)-bb, transforming growth factor
beta (TGF-β), tumor necrosis factor alpha (TNF-α), and
macrophage colony-stimulating factor (M-CSF) showed
most measurements to be near or below the detection
limit. Vascular endothelial growth factor (VEGF),
plasminogen activator inhibitor 1 (PAI-1), IL-23, CXCL11
(IFN-inducible T-cell α chemoattractant; I-TAC), macro-
phage migration inhibitory factor (MIF), IL-6, and sCD40
were detectable, but exhibited no significant changes over
time or between age groups. Analysis of CCL2 (MCP-1)
revealed no significant difference at any time-point between
juvenile and aged animals, but there was a significant
decrease over time in the aged animals (Figure 8A). CCL4
(MIP-1b) concentrations were significantly higher in the
aged cohort at the pre-immunization time-point, but this
significant difference disappeared at the post-immunization
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Figure 8 Multiplex analysis of chemokines. Cerebrospinal fluid (CSF) levels of (A) CCL2, (B) CCL4, (C) CXCL10 and (D) CCL5 before (week 0) and
after (weeks 4 and 16) immunization . Mean± SD (Aged animals, n= 9; juveniles, n= 8).
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follow-up time-points (Figure 8B). Analysis of CXCL10
(IFN-γ-induced protein 10 (IP-10) and CCL5 (regulated
upon activation, normally T-cell expressed, and presumably
secreted; RANTES) showed a significant effect of age in the
repeated measures two-way ANOVA (CXCL10, P< 0.05;
CCL5, P< 0.01) with overall higher levels in the aged
animals but no significant trend over time (Figure 8C,D).
Discussion
Active and passive anti-Aβ immunization strategies are
among the most aggressively tested therapeutic approaches
in the battle against AD. After disappointing early results in
human clinical trials, several groups have advocated a tran-
sition to preventive immunization strategies, that is, vaccin-
ation at a preclinical stage [13,16,41]. In rodent models,
preventive immunization strategies were effective in dimin-
ishing the accumulation of Aβ in the brain and reducing
cognitive impairment [2,6,9]. Although aged NHPs with
existing AD-like pathology have been successfully vacci-
nated against Aβ [32], few aged NHPs without AD path-
ology have been evaluated, showing no differences in
hippocampal levels of soluble and insoluble Aβ or cytokines
(TNF-α, IL-1α, IL-1β) between Aβ- and control-immunized
animals [42].
We chose a NHP model for our studies because of the
close genetic relationship to humans, identical APP amino
acid sequence, and natural development of neuritic
amyloid plaques and amyloid angiopathy with age. How-
ever, we also recognize the differences between humans
with AD and NHP models [43], such as less severe tau
pathology, different binding characteristics to PiB, and as
our data demonstrate, significant differences in CSF
biomarkers. Compared with non-demented aged humans
[20,21], the aged macaques in our study had lower CSF Aβ
and total tau levels and higher tau:Aβ42 ratios. Plaques are
seen in most rhesus macaques older than 21–23 years
[44,45] and cynomolgus macaques older than 18–20 years
[46,47]; data on plaque occurrence in pigtailed macaques
are lacking. The animals in our study were right within the
age range at which plaques are first seen in these species,
but their degree of pathology was milder than expected
from previous reports, and unlikely to be associated with
cognitive symptoms. Based on the pathologic findings, all
our animals would be considered to be in a preclinical
state and good candidates for a preventive immunization
trial. However, it could be argued that the absence of sig-
nificant differences in the CSF biomarkers tau and Aβ42
and the tau:Aβ42 ratio between aged and juvenile control
animals at study onset does not accurately reflect the case
in humans, for whom the use of biomarkers is advocated
for identifying preclinical disease. On the other hand, re-
cent studies have highlighted the potential utility of
YKL40 in a panel of CSF biomarkers to distinguish cogni-
tively normal people from patients with very mild or mild
dementia [18]. We observed a significant difference in CSF
YKL40 levels between aged and juvenile animals, closely re-
sembling the age- and disease-associated increases seen in
humans [18,22], suggesting that our aged cohort had
entered a phase of neuropathologic decline.
There were no differences in the degree of Aβ deposi-
tion between immunized and non-immunized aged
macaques; however, our follow-up period of six months
was probably too short to witness any significant effects
on cerebral Aβ accumulation, in particular considering
the large variability in Aβ pathology in this age group,
the small group size, and the heterogeneous genetic
background of our animals. Despite these limitations,
more detailed analysis revealed significant changes in the
composition of oligomer species in immunized versus
non-immunized aged animals, with increased ratios of
lower oligomer species, predominantly dimers. Our find-
ings suggest that even in the absence of significant amyl-
oid build-up in the brain, anti-Aβ antibodies shift
parenchymal oligomeric composition to smaller species,
thereby possibly promoting Aβ clearance from the brain.
Interestingly, we found a significant positive correlation
between increasing CSF Aβ42 levels post-immunization
and strength of the CSF humoral immune response, sug-
gesting that antibodies facilitate Aβ mobilization. This
effect may be explained by CSF antibodies either pro-
moting an Aβ shift from the brain parenchyma to the
CSF or, alternatively, slowing Aβ clearance from the CSF
compartment. As a similar effect was seen in both juve-
niles and aged animals with varying brain amyloid loads,
the increased CSF Aβ levels appeared independent of
brain Aβ levels. These results, however, are in contrast
to a previous study that noted a decrease in CSF Aβ
levels after immunization in NHPs with more advanced
amyloid pathology [32].
Soluble oligomers are increased in human AD brain
tissue, and are more strongly associated than fibrillar Aβ
with synaptotoxicity and cognitive impairment [33,48-52].
In particular, toxicity has been attributed to dimers, but also
to trimers, pentamers, and dodecamers [33,50,53,54]. Lim-
ited data from the first human active immunization trial
(AN-1792) demonstrated that immunization reduced oligo-
mer levels in the frontal cortex [55]. Mass spectrometric
analysis of brain extracts from three immunized patients
showed a preponderance of dimeric Aβ oligomers [56]. It is
unclear if the shift in oligomer composition observed after
immunization in our study would have any transient or per-
manent biologic effects. Coadministration of anti-Aβ anti-
bodies with oligomers or treatment with oligomer-specific
antibodies prevented the synaptotoxic effects of oligomers
in vitro and in vivo [50,57-60], thus, it may be speculated
that antibodies induced by immunization would capture oli-
gomers and prevent any synaptotoxic side-effects mediated
by more toxic amyloid species.
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Amyloid clearance after immunization is mediated by
microglia-dependent and -independent mechanisms
[1,61-65]. Neuropathologic examination of brains from
deceased participants of the human AN1792 trial found
evidence of Aβ phagocytosis by microglia [66,67]. To
explore the largely unknown role of microglia in preventive
immunization, we used both longitudinal monitoring via
repeated [11C]PK11195 PET imaging and CSF analysis, and
histopathologic and PCR analyses at time of necropsy.
These studies did not reveal any significant differences in
microglial density or activation between immune respon-
ders, non-responders, and non-immunized aged control
animals, but a subset of chemokines (CCL2, CCL4, and
CXCL10) had either increased baseline CSF levels in aged
animals and/or a decline post-immunization in aged but
not juvenile animals. Elevation of these inflammatory
markers in AD or even MCI has been previously described
[68-70], but their relationship to oligomers is unclear.
Further studies are needed to determine if the change in
oligomer composition in our animals is linked to the
modest decline in inflammatory markers after immunization.
A wide spectrum of macrophage differentiation states
exists, which are chiefly categorized into classical (M1)
and alternative (M2) activation states, with distinct species-
specific gene expression patterns and biologic functions
[71-74]. However, there are conflicting data in the literature
as to which activation state may be more beneficial for
Aβ phagocytosis [75-79]. We identified simultaneous
expression of various M1 and M2 markers in the aged
brain post-mortem, but did not detect any significant
immunization-related changes, suggesting that preventive
vaccination has no major effect on the cerebral M1:M2
balance.
A well-known phenomenon with aging is diminished
function of both the adaptive and innate arms of the
immune system. This includes an increased threshold for
immune response induction, which may be overcome by
supplementing a vaccine with an appropriate immunosti-
mulatory adjuvant [80]. We chose MPL, a derivative of the
lipid moiety of lipopolysaccharide, which targets toll-like
receptor 4 (TLR4) [81], and is already in clinical use in
several vaccines [82]. TLRs are evolutionarily conserved
pathogen receptors, but their function and expression is
also affected by immunosenescence [83]. It has therefore
been speculated that modulation of the innate immune
system with TLR ligands may overcome these age-related
functional changes and improve vaccine effectiveness in
the elderly [84]. Nevertheless, immunosenescence was still
evident in our study with vaccinations markedly less
effective in the aged cohort. Neither of the adjuvants
(aluminum phosphate for tetanus toxoid or MPL for the
Aβ vaccine), was able to overcome this age-related decline
in the immune response. Since the initiation of our study,
many novel vaccine modifications have been developed. It
remains to be seen if improved vaccine designs will lead to
a higher rate of elderly immune responders.
In our study, the first dose of the Aβ vaccine was
administered simultaneously with the tetanus control
vaccine, thus we cannot exclude the possibility that
coadministration affected the immune response to either
vaccine. Although vaccine coadministration can induce
both positive and negative effects on vaccine immuno-
genicity, most studies show little effect of tetanus/
diphtheria vaccine on the immune response to other
coadministered antigens [85-87]. The vaccine dose in
our study of 100 μg Aβ per injection was slightly higher
(about three times) than that used in the human
AN1792 trial [10] when adjusted for the differences in
body weight, but lower than in previous NHP studies
[32,42], supporting the overall clinical and translational
relevance of our findings.
Conclusions
In this study, we found that preventive Aβ immunization
is a safe therapeutic approach without serious side-effects
in our aged and juvenile NHPs. Immunization did not
induce increased inflammation, neither of the autoimmune/
encephalitic type nor of the innate arm of the immune
system. Although no effect on overall brain Aβ levels was
seen, a shift in the composition of soluble oligomers
towards smaller species was observed, leading us to specu-
late that this shift might facilitate the removal of toxic Aβ
species from the brain. Even if these changes are small, they
may have a significant influence over time on the balance
between Aβ accumulation and clearance.
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ethanesulfonic acid; MPL: Monophosphoryl lipid A; MRC1: Mannose receptor
1 (CD206); NHP: Non-human primate; PBS: Phosphate-buffered saline;
PET: Positron emission tomography; PiB: Pittsburgh Compound B;
PTGS2: Prostaglandin-endoperoxide synthase 2 (cyclooxygenase 2);
SDS: Sodium dodecyl sulfate; SUVR: Standardized uptake value ratio;
SWMR: Subcortical white-matter ratio; TBS: Tris-buffered saline; TBS-T:
Tris-buffered saline plus Tween; TOI: Time of injection; TLR: Toll-like receptor;
TSPO: Translocator protein; VOI: Volume of interest.
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